BiotechTube

Edoxaban low dose + Edoxaban high dose

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Deep Vein Thrombosis

Conditions

Deep Vein Thrombosis, Venous Thromboembolism

Trial Timeline

Nov 5, 2014 → Sep 16, 2021

NCT ID
NCT02303431

About Edoxaban low dose + Edoxaban high dose

Edoxaban low dose + Edoxaban high dose is a phase 1 stage product being developed by Daiichi Sankyo for Deep Vein Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02303431. Target conditions include Deep Vein Thrombosis, Venous Thromboembolism.

What happened to similar drugs?

4 of 12 similar drugs in Deep Vein Thrombosis were approved

Approved (4) Terminated (2) Active (8)
✅Dalteparin sodium injection + WarfarinPfizerApproved
✅Low Molecular Weight Heparin (dalteparin)PfizerApproved
✅ApixabanPfizerApproved
✅ClexaneSanofiApproved
🔄Apixaban + Unfractionated Heparin (UFH) + WarfarinPfizerPhase 3
🔄Enoxaparin + Placebo + Apixaban + PlaceboBristol Myers SquibbPhase 3
🔄Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placeboBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02303431Phase 1Completed

Competing Products

20 competing products in Deep Vein Thrombosis

See all competitors
ProductCompanyStageHype Score
edoxaban tosylate + enoxaparin/unfractionated heparin + warfarinDaiichi SankyoPhase 2
35
Fragmin (dalteparin sodium )PfizerPre-clinical
26
FluconazolePfizerPre-clinical
26
Dalteparin sodium injection + WarfarinPfizerApproved
43
Low Molecular Weight Heparin (dalteparin)PfizerApproved
43
Apixaban + Unfractionated Heparin (UFH) + WarfarinPfizerPhase 3
40
ApixabanPfizerApproved
35
ApixabanBristol Myers SquibbPhase 2
35
Enoxaparin + Placebo + Apixaban + PlaceboBristol Myers SquibbPhase 3
40
Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placeboBristol Myers SquibbPhase 3
40
ApixabanBristol Myers SquibbPre-clinical
26
Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placeboBristol Myers SquibbPhase 3
40
EnoxaparinSanofiPre-clinical
26
ClexaneSanofiApproved
35
Idrabiotaparinux sodium + Idraparinux sodium + Avidin + Placebo (for Avidin)SanofiPhase 3
40
SanOrg34006 + LMW heparin + Unfractionated heparin + Vitamin K antagonist (VKA)SanofiPhase 3
40
Rivaroxaban (Xarelto, BAY59-7939) + Standard of careBayerPre-clinical
23
Rivaroxaban (Xarelto, BAY59-7939) + Rivaroxaban (Xarelto, BAY59-7939) + Unfractionated heparin + WarfarinBayerPhase 3
37
Rivaroxaban (Xarelto, BAY59-7939) + Recommended VTE pharmacological treatments according to international guidelinesBayerPre-clinical
23
Triptorelin Acetate 3.75mg intramuscular injectionIpsenPre-clinical
23